PAP
RARE icon

Persistent Asset Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Persistent Asset Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-320
Closed -$215K – 431
2025
Q3 		$215K Sell
320
-27,712
-99% -$831K 0.15% 129
2025
Q2 		$392K Buy
28,032
+27,712
+8,660% +$999K 0.29% 89
2025
Q1 		$258K Hold
320
– – 0.22% 88
2024
Q4 		$174K Buy
+320
New +$15.9K 0.14% 91

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Persistent Asset Partners's RARE Position: Q1 2026 in Review

Persistent Asset Partners reduced its Ultragenyx Pharmaceutical (RARE) stake by 19% in Q1 2026, selling an estimated $48.3K and leaving 8,884 shares worth $186K. The position accounts for 0.07% of the portfolio, ranked #201.

Persistent Asset Partners first reported a position in RARE in Q2 2025 and has held it in 4 quarters since. The position peaked at $452K in Q2 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Persistent Asset Partners held 8,884 shares of Ultragenyx Pharmaceutical worth $186K as of Q1 2026.
  • Persistent Asset Partners sold 2,145 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $48.3K.
  • Ultragenyx Pharmaceutical made up 0.07% of Persistent Asset Partners's portfolio in Q1 2026, its #201 holding.
  • Persistent Asset Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and has held it in 4 quarters since.
  • Persistent Asset Partners's Ultragenyx Pharmaceutical position peaked at $452K in Q2 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.